[Current state of CAR-T cell therapy for relapsed/refractory ALL in children and young adults].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Refractory and relapsed acute lymphoblastic leukemia (ALL) in pediatric and young adult patients remains difficult to treat. Recent advances in immunotherapy for B-cell hematologic malignancies, particularly CAR-T cell therapy, have significantly improved B-ALL treatment. In Japan, only tisagenlecleucel (Kymriah®) is approved for clinical use. This paper reviews improvements in pediatric ALL treatment outcomes and explores new strategies for relapsed B-ALL, with a focus on CAR-T cell therapy. Additionally, it discusses challenges in optimizing post-CAR-T treatment strategies and future prospects in this evolving field.